Displaying drugs 976 - 1000 of 1286 in total
Vatalanib
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
Investigational
OPC-14523
OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.
Investigational
CYC-065
CYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL).
Investigational
Matched Description: … CYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study …
VAD-044
VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.
Investigational
Matched Description: … VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. …
LY-517717
LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
Investigational
Matched Description: … LY517717 is an investigational oral direct inhibitor of activated Factor Xa. …
Anpocogin
Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.
Investigational
Matched Description: … Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/ …
Demexiptiline
Demexiptiline is marketed under the names Deparon or Tinoran. It is a tricyclic antidepressant which acts primarily as a norepinephrine reuptake inhibitor.
Experimental
Matched Description: … It is a tricyclic antidepressant which acts primarily as a norepinephrine reuptake inhibitor. …
AAV-dXIAP
AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
Investigational
Matched Description: … AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis …
BBT-877
BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.
Investigational
Matched Description: … BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such …
Cetilistat
Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
Investigational
Matched Description: … Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of …
Enadenotucirev
Enadenotucirev is under investigation in clinical trial NCT02636036 (Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors).
Investigational
Matched Description: … Enadenotucirev is under investigation in clinical trial NCT02636036 (Phase I Study of Enadenotucirev and PD-1 Inhibitor …
Tridolgosir
An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.
Experimental
Matched Description: … An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor …
Metrifonate
Metrifonate or trichlorfon is an irreversible organophosphate acetylcholinesterase inhibitor. It is a prodrug which is activated non-enzymatically into 2,2-dichlorovinyl dimethyl phosphate.
Vet approved
Matched Description: … Metrifonate or trichlorfon is an irreversible organophosphate acetylcholinesterase inhibitor. …
Rebastinib
Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia. It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.
Investigational
Matched Description: … It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent. …
Daglutril
Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.
Investigational
Matched Description: … Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under …
CA-074 methyl ester
CA-074 methyl ester (CA-074Me) is a cell-permeable cathepsin B inhibitor. It is converted by cellular esterases to CA-074.[A258234,A258239]
Experimental
Matched Description: … CA-074 methyl ester (CA-074Me) is a cell-permeable cathepsin B inhibitor. …
MGN-4893
MGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.
Investigational
Matched Description: … MGN-4893 is an inhibitor of microRNA-451. …
Alvespimycin
Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic...
Investigational
Matched Description: … Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. ... In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable …
TTP889
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Matched Description: … TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed ... TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic …
AZD 3355
AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Investigational
Matched Description: … AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. …
PAS-004
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
Matched Description: … PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. …
Alrizomadlin
Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.[A257281,A257286]
Investigational
Matched Description: … Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. …
Fleroxacin
Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.
Experimental
Matched Description: … Fleroxacin is not an inhibitor of CYP1A2.[A39048] …
PSN357
PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Investigational
Matched Description: … PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose …
Displaying drugs 976 - 1000 of 1286 in total